Retatrutide vs Tirzepatide vs Semaglutide — the GLP-class research comparison
Three molecules dominate the published GLP-class research literature in 2026: Semaglutide (GLP-1 mono-agonist), Tirzepatide (GLP-1 + GIP dual-agonist), and Retatrutide — referred to as GLP-RT on our catalogue for compliance reasons — the GLP-1 + GIP + glucagon triple-agonist. Each generation added a receptor target; each set of published trial data improved on the previous. The differences between them are non-trivial and matter for any researcher reading the literature.
Receptor mechanism — the three-generation story
The incretin family is a small set of gut-released hormones — primarily GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) — that trigger insulin secretion from the pancreas after a meal, slow gastric emptying, and modulate appetite at the hypothalamic level. Glucagon, a structurally related hormone, is the metabolic opposite of insulin: it mobilises glucose from liver glycogen and increases energy expenditure.
Each of the three molecules engineers different combinations of these three receptor families:
- Semaglutide — GLP-1 receptor mono-agonist. Approved for type-2 diabetes (Ozempic) and obesity (Wegovy) in non-UAE jurisdictions. The pivotal STEP trials (Wilding et al., NEJM 2021) reported a mean −14.9% body-weight reduction at 68 weeks (2.4 mg weekly dose).
- Tirzepatide — GLP-1 + GIP dual-agonist. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported a mean −20.9% body-weight reduction at 72 weeks (15-mg dose).
- Retatrutide / GLP-RT — GLP-1 + GIP + glucagon triple-agonist. The pivotal Phase 2 (Jastreboff et al., NEJM 2023) reported a mean −24.2% body-weight reduction at 48 weeks (12-mg dose). Registrational Phase 3 trials are running through 2026.
Each generation adds a receptor target and produces a larger weight-change effect in pivotal trials — but the safety profile broadens with each addition. Reading them as a linear progression misses the pharmacological distinctions.
The pivotal trial data side-by-side
Direct head-to-head trials between the three molecules have not been published as of 2026. Comparing across separate trials requires reading each pivotal study with its own enrolment criteria, dose-titration protocol, and follow-up window. The three trials enrol roughly comparable populations (BMI ≥ 30 adults with obesity, or ≥ 27 with one comorbidity) but the durations differ (68 weeks for Semaglutide STEP-1, 72 weeks for Tirzepatide SURMOUNT-1, 48 weeks for the Retatrutide Phase 2). The comparisons below are cross-trial inferences, not head-to-head data.
Weight-change endpoint at pivotal dose
- Semaglutide 2.4 mg / 68 weeks — mean −14.9% body weight
- Tirzepatide 15 mg / 72 weeks — mean −20.9% body weight
- Retatrutide 12 mg / 48 weeks — mean −24.2% body weight
The dose-response curves are dose-dependent across all three molecules. For the lowest dose-titration arms, the differences are smaller; for the highest tolerated doses, the differences widen. The Retatrutide 48-week figure on a 12-mg dose appears to extrapolate further at longer durations — the Phase 3 trials will confirm or refute this.
Cardiometabolic secondary endpoints
All three molecules improve secondary cardiometabolic endpoints in the same direction (lower systolic blood pressure, improved fasting glucose and HbA1c, improved lipid panel) in proportion to the weight change. The cardiometabolic signal is therefore not where the three molecules differentiate — they differentiate on the weight-change magnitude and the adverse-event profile.
Adverse-event profile differences
Gastrointestinal adverse events dominate the safety signal across all three molecules — nausea, diarrhoea, vomiting, constipation, dose-dependent, generally mild-moderate. The differences:
- Semaglutide — GI events run roughly 20–40% nausea, 15–25% diarrhoea. Discontinuation rate for AEs in STEP-1 was 4.5%.
- Tirzepatide — slightly higher GI rates than Semaglutide; SURMOUNT-1 reported 25–33% nausea, 19–23% diarrhoea. Discontinuation rates 4.3–7.1%.
- Retatrutide — GI rates broadly comparable to Tirzepatide on the active-dose arms. Phase 2 discontinuation rates ran 6.4–16.3% across active arms, increasing with dose. The glucagon component adds a small heart-rate increase signal (~7 bpm) that is not seen with the GLP-1 and GIP/GLP-1 agonists — worth noting in the adverse-event read.
Research availability in the UAE + GCC
None of the three molecules are sold over the counter to the public in the UAE or wider GCC. Semaglutide and Tirzepatide are available as clinic-prescribed treatments under pharmacy regulation (Ozempic, Wegovy, Mounjaro brand names where registered). Retatrutide is still investigational and is not approved anywhere as of 2026 — research supply is the only legitimate access path.
For UAE-based researchers evaluating a Retatrutide / GLP-RT research source, the framework on our GLP-RT research overview page applies: third-party HPLC at ≥ 98% peak area at λ = 214 nm, mass spectrometry molecular-weight confirmation, ICH Q7 manufacturing equivalence, and a batch-level Certificate of Analysis available on request. Buyer-side, treat any research supplier without these baselines with appropriate scepticism.
Reading the marketing claims honestly
Three patterns recur in popular accounts of the comparison that the research data does not support:
- “Retatrutide is just a stronger Tirzepatide” — the two molecules engineer different receptor architectures. The glucagon-receptor component is a meaningful pharmacological addition, not a dose increase.
- “Semaglutide is the safest because it is the oldest” — the safety profile of each molecule depends on the dose and patient population, not the year it was first approved. All three have comparable safety profiles at therapeutically equivalent doses.
- “Choosing the most aggressive molecule produces the best outcomes” — published trial data does not support extrapolation from the pivotal Phase 2 / 3 magnitude to individual outcomes. The within-trial response variance is substantial; many participants achieve much less than the trial mean, and many achieve more.
Where to go from here
For the technical read on Retatrutide specifically, see our GLP-RT (Retatrutide) research overview. The Arabic-language version is at /learn/ar/retatrutide.